Cargando...
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
CD19 is the most promising target for developing chimeric-antigen receptor (CAR) T cells against B-cell leukemic cancer. Currently, two CAR-T-cell products, Kymriah and Yescarta, are approved for leukemia patients, and various anti-CD19 CAR T cells are undergoing clinical trial. Most of these anti-C...
Gardado en:
| Publicado en: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7730610/ https://ncbi.nlm.nih.gov/pubmed/33271901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21239163 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|